Boston Scientific Corp. (BSX) News
Filter BSX News Items
BSX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BSX News Highlights
- For BSX, its 30 day story count is now at 27.
- Over the past 20 days, the trend for BSX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- QGEN, CRL and DRUG are the most mentioned tickers in articles about BSX.
Latest BSX News From Around the Web
Below are the latest news stories about BOSTON SCIENTIFIC CORP that investors may wish to consider to help them evaluate BSX as an investment opportunity.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseBoston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Citi Says Market Upside Appears Limited, but These 2 Stocks Have More Room to RunGiven the current macroeconomic backdrop, the S&P 500 has little room for further gains. That is the opinion of the analysts at Citi, who in a recent note claimed the bellwether index is reaching a valuation level that will stunt further upside. Going by present rates and various “macro inputs” like growth and inflation, the high end of Citi’s fair value framework suggests an S&P 500 price-to earnings multiple of 18.5x. With the S&P 500’s trailing price-to-earnings ratio currently hovering near |
Here's Why You Should Retain Boston Scientific (BSX) NowInvestors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device. |
Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies. |
Charles River (CRL) to Develop RNA-based Therapy With New PactCharles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients. |
IDEXX (IDXX) Aided by Global Growth, Solid Instrument PlacementIDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases. |
Charles River (CRL) to Advance DNA Programs With New LaunchCharles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond. |
NuVasive (NUVA) Suffers From Macro Headwinds, Price IssueNuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit. |
QIAGEN (QGEN) Gains From Innovation, Currency Headwind AilsThe QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth. |
Syneos Health (SYNH) to Launch Serplulimab With New PactSyneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment. |